Knowing stock market today at a glance

Bull&Bear | Arqit Quantum and DouYu Lead Gains While Blaize Holdings and Jupiter Neurosciences Tumble

Mover TrackerThursday, Jan 16, 2025 5:00 pm ET

1min read

In the realm of rising stocks, Arqit Quantum (ARQQ) experienced a notable increase, advancing by 37.35% and sustaining a three-day surge, culminating in a 68.63% rise over the past three days. The surge in Arqit Quantum's stock was largely supported by the overall strong market sentiment, following the release of CPI data that aligned with expectations and a core CPI increase that was lower than anticipated.

DouYu (DOYU) also saw a significant rise, climbing by 27.66% and marking a three-day increase of 49.71%. The increase in DouYu's stock price came after the company's board of directors approved a special cash dividend of $9.94 per share to shareholders.

ImmunityBio (IBRX) rose by 27.20%, continuing its momentum with a two-day increase of 31.03%. The company has plans to submit a Biologics License Application (BLA) in 2025 for the second and third-line treatment of non-small cell lung cancer patients who have progressed on checkpoint inhibitors.

SES AI (SES) experienced a 25.32% increase, maintaining a two-day gain of 26.78%. SES AI is scheduled to participate in the Water Tower Research Fireside Chat on Wednesday, January 15, 2025.

Rezolve AI (RZLV) also saw an increase of 24.90%, with a two-day rise of 30.30%. Maxim Group initiated coverage with a buy rating and set a price target of $10 for Rezolve AI.

On the flip side, facing a downturn in stock performance, Blaize Holdings (BZAI) witnessed a 32.29% decrease, marking a three-day decline, with a notable drop of 24% on its second day on Nasdaq. Meanwhile, Atomera (ATOM) suffered a decline of 24.80%, potentially marking its largest percentage decline since April 2021, with the stock falling over 21%.

Jupiter Neurosciences (JUNS) fell by 20.93%, experiencing a five-day decrease totaling 50.64%. The company announced a strategic focus in its clinical trials targeting neurodegenerative diseases, particularly in the treatment of the NLRP3 inflammasome using its JOTROL platform.

Biard Medical (BDMD) saw an 18.13% drop, with a three-day decrease reaching 51.22%, having declined over 42% pre-market. Meanwhile, Zentalis Pharmaceuticals (ZNTL) reported a 16.14% drop in its stock. The company announced the issuance of incentive grants in accordance with Nasdaq listing rule 5635(c)(4).

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.